Biotechnology and the creation of novel probiotic preparations based on the Bacillus-type bacteria, which can be used for the prevention and treatment of infectious diseases in humans and of dysbiosis of various etiologies. The biological preparation for the prevention and treatment of infectious diseases, primarily tuberculosis, dysbiosis of various etiologies, and candidiasis, comprising live microbial mass of Bacillus subtilis VKPM B-8611 Bacillus licheniformis VKPM B-8610 strains, wherein said preparation additionally comprises live culture filtrates of said Bacillus subtilis Bacillus licheniformis strains and a lectin-binding substance comprising a live microbial mass culture fluid supernatant of the Lactobacillus fermentum 90 TS-4(21) strain in the following component ratio: a live microbial mass of the Bacillus subtilis VKPM B-8611 strain—at least 5×108 CFU a live microbial mass of the Bacillus licheniformis VKPM B-8610 strain—at least 2×108 CFU a lyophilized filtrate of live microbial mass of the Bacillus subtilis strain VKPM B-8611, 2.5-4.5 mg a lyophilized filtrate of live microbial mass of the Bacillus licheniformis strain VKPM B-8610, 2.5-4.5 mg and a lyophilized lectin-binding substance including a culture fluid supernatant of live microbial mass of the Lactobacillus fermentum 90 TS-4(21) strain with the molecular weight exceeding 20 kDa. 5.5-7.5 mg, and 1 i.c., 2 d.c., 1 il. 7 tabl.
